Trial Profile
A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 09 May 2014 New trial record
- 18 Oct 2013
- 07 Mar 2008